scholarly journals Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment.

1995 ◽  
Vol 79 (10) ◽  
pp. 922-925 ◽  
Author(s):  
B C Polak ◽  
G S Baarsma ◽  
B Snyers
Author(s):  
D. Ángel-Pereira ◽  
P. Rocha-Cabrera ◽  
L. Cordovés-Dorta ◽  
M.J. Losada Castillo ◽  
A. Blasco Alberto ◽  
...  

2018 ◽  
Vol 64 (1) ◽  
pp. 17-21
Author(s):  
Gyula Laszlo Fekete ◽  
László Fekete

AbstractObjectives: The aim of this clinical and therapy study was to evaluate the efficacy of NB-UVB phototherapy versus systemic therapy in moderate-to-severe atopic dermatitis of the adult.Material and methods: The subjects of the study were divided into two groups of 25 adult patients with moderate and severe atopic dermatitis according to the inclusion criteria. The first group of 25 patients were treated with systemic corticosteroids while the second group of 25 patients were treated with NB-UVB phototherapy. At the end of the study, after all the data were centralized, we performed a statistical analysis of the results, comparing the two groups as well as the efficacy of the different therapies.Results: In group I the clinical efficacy of the systemic corticosteroid treatment was achieved, on average, at 4 weeks in patients with moderate atopic dermatitis and at 6 weeks in patients with severe atopic dermatitis. In group II the clinical effecacy of NB-UVB phototherapy was achieved, on average, at 6 weeks for patients with moderate atopic dermatitis and at 8 weeks for those with the severe form. In both groups, the total IgE serum levels were elevated at the beginning, and they became normal throughout the clinical improvement. Remarkable therapy-related side effects were found in the first study group.Conclusion: We conclude that NB-UVB phototherapy had similar efficacy in treating moderate-to-severe atopic dermatitis with minimal side effects compared to systemic corticosteroid therapy.


2019 ◽  
Vol 104 (3) ◽  
pp. 345-349 ◽  
Author(s):  
Toshinobu Kubota ◽  
Masao Katayama ◽  
Reiko Nishimura ◽  
Suzuko Moritani

AimsTo determine the long-term outcomes of ocular adnexal lesions in immunoglobulin G4-related ophthalmic disease (IgG4-ROD).MethodsThis retrospective, non-randomised exploratory study included 82 patients with ocular adnexal lesions. We evaluated the long-term outcomes in 71 patients during the median follow-up period of 30 months, who underwent either watchful waiting (n=20; range 12–90 months) or systemic corticosteroid treatment, delivered according to consensus guidelines (n=51; range 9– 115 months). We also analysed factors that might contribute to recalcitrance to treatment.ResultsOf 82 patients, 40 (49%) were male, and the median patient age was 60 years old. Twenty-one (26%) patients with extraocular muscle (EOM) and/or trigeminal nerve branch (CN V) enlargements had a significantly high frequency of multiple ocular adnexal lesions (p<0.0001, Fisher’s exact test). In addition, two patients developed EOM and/or CN V enlargements de novo over time. Twenty patients with solitary lacrimal gland enlargements preferred watchful waiting, due to mild symptoms. Of these, 18 (90%) lesions remained dormant throughout a median follow-up of 27 months. Among 51 patients treated with corticosteroids, 31 (61%) experienced relapses after treatment and required systemic low-dose maintenance treatment. A multivariate analysis indicated that EOM and/or CN V enlargements comprised a risk factor for relapse (HR 2.7; 95% CI 1.1 to 6.7).ConclusionsThis exploratory study showed that different types of ocular adnexal lesions in IgG4-ROD displayed distinct proliferative activities. Our results suggested that EOM and/or CN V enlargements might be secondary lesions that confer refractoriness to systemic corticosteroid treatment recommended by consensus guidelines.


1982 ◽  
Vol 185 (1) ◽  
pp. 7-14 ◽  
Author(s):  
C.H.O.M. von Winning ◽  
J.A. Oosterhuis ◽  
A.H. Renger-van Dijk ◽  
H. Hornstra-Limburg ◽  
B.C.P. Polak

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Kao-Sung Tsai ◽  
Chia-Sung Yen ◽  
Po-Yuan Wu ◽  
Jen-Huai Chiang ◽  
Jui-Lung Shen ◽  
...  

Epidemiological studies have shown a strong association between dermatitis and stroke. Systemic corticosteroid, the mainstay treatment for dermatitis, could enhance the atherosclerotic process. Traditional Chinese Medicine (TCM) has been used for dermatitis to decrease the side effects of corticosteroid. However, the different stroke risk in dermatitis patients treated with systemic corticosteroid or TCM remains unclear. This study identified 235,220 dermatitis patients and same comorbidity matched subjects between 2000 and 2009 from database of NHRI in Taiwan. The two cohorts were followed until December 31, 2011. The primary outcome of interest was new diagnosis of stroke. The crude hazard ratio (HR) for future stroke among dermatitis patients treated with systemic corticosteroid was 1.40 (95% CI, 1.34–1.45;P<0.0001) and TCM was 1.09 (95% CI, 1.05–1.13;P<0.0001). The log-rank test showed a higher cumulative incidence of ischemic stroke in the patient treated with only systemic corticosteroid group than that treated with systemic corticosteroid and TCM, only TCM, and neither systemic corticosteroid nor TCM in the matched cohort during the follow-up period (P<0.0001). We demonstrated that patients treated with systemic corticosteroid had an increased risk of stroke and that the risk probably decreased by TCM treatment.


Author(s):  
A Vivekanandan ◽  
B Santyr ◽  
A Ranger

Background: Pseudotumoral hemicerebellitis is an acute, unilateral inflammation of the cerebellum that typically affects the pediatric population. The etiology remains to be elucidated, however frequently is attributed to post-infectious inflammation. Though it tends to be self-resolving, treatment may reduce the time to symptomatic recovery. Systemic corticosteroid therapy has been proposed as a mechanism for improving outcomes and time to symptomatic recovery. Methods: We present a case report of a 12-year-old male with pseudotumoral hemicerebellitis and unilateral cerebellar dysfunction. Additionally, we briefly review the additional 35 reported cases of pseudotumoural hemicerebellitis with respect to length of time to symptomatic recovery with or without systemic corticosteroid treatment. Results: 30 cases reported length of time to symptomatic recovery. Including our case, the mean time to recovery for those treated with systemic corticosteroids (n=20) was 48.05 days(SE=16.3). The mean time to recovery for those treated without (n=10) was 86.7 days(SE=29.3). Conclusions: Treatment with systemic corticosteroids was associated with a faster time to symptomatic recovery compared to without. Regardless of etiology, reducing inflammation and mass effect involved in pseudotumoral hemicerebellitis may be integral to a more rapid return to neurological baseline.


Sign in / Sign up

Export Citation Format

Share Document